Value-Based Prices Could Establish Common Ground on Heart Failure Drug Pricing and Coverage
- PMID: 35738714
- DOI: 10.1016/j.jacc.2022.04.032
Value-Based Prices Could Establish Common Ground on Heart Failure Drug Pricing and Coverage
Keywords: cost-effectiveness; health policy; heart failure.
Conflict of interest statement
Funding Support and Author Disclosures Dr Wasfy is supported by the American Heart Association (18 CDA 34110215) and has been supported by the National Institutes of Health (R01AG062282 and KL2 TR001100); has received consulting fees from Pfizer; has received honoraria from the Institute for Clinical and Economic Review; and currently serves as chair of the New England Comparative Effectiveness Public Affairs Advisory Council. Dr O’Kelly has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.J Am Coll Cardiol. 2022 Jun 28;79(25):2516-2525. doi: 10.1016/j.jacc.2022.04.031. J Am Coll Cardiol. 2022. PMID: 35738713 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
